Jump to main content
Jump to site search

Issue 4, 2010
Previous Article Next Article

Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

Author affiliations

Abstract

Burkitt's lymphoma (BL) is a particularly aggressive cancer that primarily affects African children. Unfortunately, effective and affordable treatment is out of reach of most of the afflicted. The illicit psychoactive drug methylenedioxymethamphetamine (MDMA, ‘ecstasy’) is cytotoxic to BL cell lines, but its low potency, psychoactivity and neurotoxicity preclude consideration as a therapeutic drug candidate. This paper describes the discovery of novel α-aryl analogues of MDMA that lack psychoactivity and reduce BL cell line viability with significantly more potency than the lead compound. Preliminary in vitro studies also indicate that the compounds are non-toxic to a relevant neuronal cell line.

Graphical abstract: Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

Back to tab navigation

Supplementary files

Publication details

The article was received on 12 Jul 2010, accepted on 30 Jul 2010 and first published on 07 Sep 2010


Article type: Concise Article
DOI: 10.1039/C0MD00108B
Citation: Med. Chem. Commun., 2010,1, 287-293
  •   Request permissions

    Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

    M. N. Gandy, M. McIldowie, K. Lewis, A. M. Wasik, D. Salomonczyk, K. Wagg, Z. A. Millar, D. Tindiglia, P. Huot, T. Johnston, S. Thiele, B. Nguyen, N. M. Barnes, J. M. Brotchie, M. T. Martin-Iverson, J. Nash, J. Gordon and M. J. Piggott, Med. Chem. Commun., 2010, 1, 287
    DOI: 10.1039/C0MD00108B

Search articles by author

Spotlight

Advertisements